Ignite Creation Date:
2025-12-24 @ 7:12 PM
Ignite Modification Date:
2025-12-25 @ 4:47 PM
Study NCT ID:
NCT06395103
Status:
RECRUITING
Last Update Posted:
2025-12-24
First Post:
2024-02-01
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
Sponsor:
Merck Sharp & Dohme LLC
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2024-08-16
Start Date Type:
ACTUAL
Primary Completion Date:
2029-03-31
Primary Completion Date Type:
ESTIMATED
Completion Date:
2029-03-31
Completion Date Type:
ESTIMATED
First Submit Date:
2024-02-01
First Submit QC Date:
None
Study First Post Date:
2024-05-01
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-12-23
Last Update Post Date:
2025-12-24
Last Update Post Date Type:
ACTUAL